Table 1.
Clinical profiles of subjects (n=256)
| Chronic hepatitis (F0 to F3) | Liver ciorrhosis (F4) | |
|---|---|---|
| Number | 229 | 27 |
| Observation periods (yrs) | 5.9±3.4 | 6.9±4.4 |
| Age (yrs) | 59.5±11.6 | 65.3±10.7 |
| Gender (males) | 55.6% | 41.3% |
| AST (U/L) | 55.6±38.1 | 82.0±35.1 |
| ALT (U/L) | 75.5±60.7 | 99.4±55.2 |
| r-GT (U/L) | 59.6±61.3 | 62.7±41.5 |
| ALP (U/L) | 265.5±99.3 | 322.1±132.9 |
| Total bilirubin (mg/dl) | 0.64±0.27 | 0.71±0.23 |
| Platelet counts(x104) | 18.1±5.9 | 13.2±3.9 |
| Total protein (g/dl) | 7.25±0.63 | 7.40±0.56 |
| Albumin (g/dl) | 4.07±0.39 | 4.03±0.77 |
| Prothrombin time (%) | 96.7±6.6 | 7.40±0.56 |
| BTR | ||
| BCAA | ||
| Tyrosine | ||
| Ammonia (µg/dl) | 54.4±22.1 | 41.6±16.8 |
| ICGR15 (%) | 8.0±5.2 | 15.8±8.5 |
| Zinc concetration (µg/dl) | 75.6±13.5 | 71.4±13.8 |
| F stages | ||
| F0 | F0: 2 (0.9%) | |
| F1 | F1: 124 (54.1%) | |
| F2 | F2: 66 (28.8%) | |
| F3 | F3: 37 (16.2%) | |
| F4 | 27 | |
| HCV RNA | ||
| High | 87.7% | 91.1% |
| Low | 12.3% | 8.9% |
| Serotype | ||
| 1 | 87% | 89.3% |
| 2 | 13% | 10.7% |
p was calculated by ANOVA, CH, chronic hepatitis; LC, liver cirrhosis; AST, aspartate amino transferase; ALT, Alanin aminotransferase; ALP, Alkaline Phosphatase; Γ-GT, γ-glutamyltransferase; ICGR15, the retention rate of indocyanine green 15 min; HCV RNA high, ≧106 copy/ml; HCV RNA low, <105 copy/ml.